<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373656</url>
  </required_header>
  <id_info>
    <org_study_id>CCGChina-CCSR-V</org_study_id>
    <nct_id>NCT03373656</nct_id>
  </id_info>
  <brief_title>Vaccination for Children of H&amp;O and Their Parents</brief_title>
  <official_title>Study on Compliance, Safety and Effectivity of Vaccination for Children With Hematologic Malignancies or Solid Tumors and Their Parents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer Group, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Pudong District Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Cancer Group, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study on compliance, safety and effectivity of vaccination
      for children with hematologic malignancies or solid tumors and their parents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with hematologic malignancies or solid tumors are all facing with immune deficiency
      due to the disease, the chemotherapy, the hematopoietic stem cell transplantation or the
      splenectomy, which greatly increases their chance to get infectious diseases. In this study,
      we will assess the compliance of children with hematologic malignancies or solid tumors and
      their parents to accept vaccination after finishing treatments, follow up with untoward
      effect questionnaires to assess the safety, obtain the serum of children patients to test
      antibody titers and assess the effectivity, provide clues for the study of vaccination in
      children with hematologic malignancies or solid tumors and provide a scientific basis for the
      formulation and reunification of vaccination programs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of parents of children willing to be vaccinated after receiving relevant knowledge propagation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with vaccination-related adverse events</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of serum antibody increased after vaccination</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Vaccination</condition>
  <condition>Hematologic Malignancy</condition>
  <condition>Solid Tumor, Childhood</condition>
  <arm_group>
    <arm_group_label>low antibody titers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibody titers lower than protection level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high antibody titers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Antibody titers higher than protection level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination</intervention_name>
    <description>Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:
hepatitis B vaccine measles-rubella combined vaccine</description>
    <arm_group_label>low antibody titers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Vaccination</intervention_name>
    <description>Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.</description>
    <arm_group_label>high antibody titers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children patients(â‰¤18 years) who accepted chemotherapy, hematopoietic stem cell
             transplantation or splenectomy since our study started.

          2. No history of hepatitis B and measles, do not suffer from other diseases that affect
             immune function and allergic diseases.

        Exclusion Criteria:

          1. Children patients who did not reach clinical remission after treatment, critically ill
             or eventually died.

          2. Patients who used monoclonal antibodies, especially anti-tumor necrosis factors.

          3. Intermittent or low-dose chemotherapy or other immunosuppressive drugs users.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Jin Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Jin Gao, MD</last_name>
    <phone>86-21-38626161</phone>
    <phone_ext>82064</phone_ext>
    <email>gaoyijin@scmc.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xing-Wei Wang, MD</last_name>
    <phone>86-21-38626161</phone>
    <phone_ext>82064</phone_ext>
    <email>wangxingwei@scmc.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Jin Gao, MD</last_name>
      <phone>0086-21-38626161</phone>
      <email>gaoyijin@scmc.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xing-Wei Wang, MD</last_name>
      <phone>0086-21-38626161</phone>
      <email>wangxingwei@scmc.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Childhood</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Immune Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

